Chee KayCheung United KingdomUniversity of Leicester

Chee KayCheung
Dr. Chee Kay Cheung is a Consultant Nephrologist and Honorary Associate Professor, University of Leicester, UK. His PhD examined factors that contribute towards progressive kidney damage in IgA nephropathy, and current interests are in clinical trials in glomerular diseases, especially in IgAN. He leads a number of investigator-initiated studies in this area in collaboration with pharmaceutical companies and academic partners, and has served as UK national chief investigator and principal investigator on multiple clinical trials. He leads specialist clinics in glomerular diseases and in vasculitis and lupus nephritis. He is a steering committee member and active member of several national working groups, including the UK glomerular diseases clinical studies group and UK IgAN and membranous nephropathy rare disease groups.
Institution

Day 1 - Sunday April 14, 2024

Time Session
9 a.m.
10:30 a.m.
Precise Phenotyping and Treatment
SK01
HeatherReich Chairperson CanadaUniversity of Toronto, University Health Network
SebastiánJaurretche Chairperson sebastianjaurretche@hotmail.comArgentinaSanatorio Parque SA
  • Deciphering the IGAN Cell Atlas
    JulioSaez-Rodriguez Speaker julio.saez@uni-heidelberg.deGermanyHeidelberg University
  • Complement-mediated Kidney Diseases in the Era of Complement Inhibitors
    MarinaVivarelli Speaker marina.vivarelli@opbg.netItalyLaboratory of Nephrology, Bambino Gesù Children's Hospital
  • CART-T
    JonathanHogan Speaker jonathan.hogan@cabalettabio.comCabaletta Bio
  • New Targets to Reduce the Burden of Rare Kidney Diseases
    LauraMariani Speaker lmariani@umich.eduUnited StatesUniversity of Michigan
  • Q and A
Hall C4
10:30 a.m.
11 a.m.
Hitting the Four Hits: The Potential of Dual BAFF/APRIL Inhibition in IgA Nephropathy
SPOT-O3
JonathanBarratt Spotlight Speaker United KingdomUniversity of Leicester, Leicester, UK
Spotlight Stage 1 (exhibition hall)

Day 2 - Monday April 15, 2024

Time Session
12:45 p.m.
1:30 p.m.
Keys to success to be on top of what is published in nephrology (ISN-ACT)
SPOT-15
AndreaViecelli Spotlight Speaker AustraliaUniversity of Queensland
Augusto CesarSoares dos Santos Junior Spotlight Speaker BrazilHospital das Clinicas, UFMG; Fac Ciências Medicas
BrendanSmyth Spotlight Speaker brendan.smyth@sydney.edu.auAustralia
DavidWheeler Spotlight Speaker United KingdomUniversity College London
MegJardine Spotlight Chairperson AustraliaNHMRC Clinical Trials Centre, University of Sydney, Australia
Spotlight Stage 1 (exhibition hall)
3 p.m.
4 p.m.
Late Breaking Clinical Trials Session
LBCT
AlessiaFornoni Chairperson United StatesUniversity of Miami
MichelleRheault Chairperson rheau002@umn.eduUnited StatesUniversity of Minnesota
  • Predicting the Risks of Kidney Failure and Death in Adults With Moderate-to-severe Chronic Kidney Disease (KDpredict)
    PietroRavani Free Communication pravani@ucalgary.caCanadaUniversity of Calgary
  • Plasma Exchange in ANCA Associated Vasculitis GN: Update After Pexivas
    Wladimir MietekSzpirt Speaker wladimir.mietek.szpirt.01@regionh.dkDenmarkRigshospitalet, University of Copenhagen, Dept. of Nephrology, Denmark, Senior Research Consultant
  • EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY
    DanaRizk Free Communication drizk@uabmc.eduUnited StatesUniversity of Alabama at Birmingham
  • SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL
    JonathanBarratt Free Communication United KingdomUniversity of Leicester, Leicester, UK
  • PREGNANCY AMONG WOMEN ON CHRONIC DIALYSIS : THE FRENCH COHORT
    CécileCouchoud Free Communication cecile.couchoud@biomedecine.frFranceREIN registry, Agence de la biomédecine, France
Hall A
4:30 p.m.
5:30 p.m.
Designing Smart Clinical Trials
SK05
DebbieGipson Chairperson debbie.gipson@nih.govUnited StatesNational Institutes of Health/NIDDK
JonathanBarratt Chairperson United KingdomUniversity of Leicester, Leicester, UK
  • Patients Subphenotyping: The Example of Diabetic Kidney Disease
    John CijiangHe Speaker cijiang.he@mssm.eduUnited StatesIcahn School of Medicine at Mount Sinai
  • Power of AI to Develop Data-driven Early Detection, Diagnosis, and Management of Kidney Disease
    LauraMariani Speaker lmariani@umich.eduUnited StatesUniversity of Michigan
  • Targeted Approaches in Clinical Trial Design
    HiddoLambers Heerspink Speaker H.J.Lambers.Heerspink@umcg.nlNetherlands
  • Q and A
Hall D

Pre-Congress - Saturday April 13, 2024

Time Session
11:30 a.m.
1:30 p.m.
Primer Course in Glomerular Disease: A Case-Based Approach: Nephrotic Syndrome
GN2
AdrianLiew Chairperson SingaporeMount Elizabeth Novena Hospital, Singapore
HeatherReich Chairperson CanadaUniversity of Toronto, University Health Network
HernánTrimarchi Chairperson ArgentinaHOSPITAL BRITÁNICO DE BUENOS AIRES
JonathanBarratt Chairperson United KingdomUniversity of Leicester, Leicester, UK
  • Approach to Nephrotic Syndrome
    Chee KayCheung Speaker ckc15@leicester.ac.ukUnited KingdomUniversity of Leicester
  • Case Presentation and Discussion 2
    MarinaVivarelli Speaker marina.vivarelli@opbg.netItalyLaboratory of Nephrology, Bambino Gesù Children's Hospital
  • Case Presentation and Discussion 3
    KeishaGibson Speaker keisha_gibson@med.unc.eduUnited StatesUniversity of North Carolina at Chapel Hill, USA
  • Case Presentation and Discussion 4
    HeatherReich Speaker CanadaUniversity of Toronto, University Health Network
Hall E